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1. Introduction 
Acute bronchitis, one of the most common diagnoses in ambulatory care medicine, 
accounted for approximately 2.5 million visits to U.S. physicians in 1998 (Slusarcick & 
McCaig, 2000). This condition consistently ranks as one of the top ten diagnoses for which 
patients seek medical care, with cough being the most frequently mentioned symptom 
necessitating office evaluation (Knutson & Braun, 2002; Saldías et al., 2007). The diagnosis is 
based on clinical findings, without standardized diagnostic signs and sensitive or specific 
confirmation laboratory tests (Oeffinger et al., 1997). 
Acute bronchitis is usually caused by a viral infection, especially by influenza, parainfluenza 
and respiratory syncytial virus, it is also caused by adenovirus, coronavirus and rhinovirus 
(Marrie, 1998). When microbiological studies are performed, less than 10-20% of patients 
will have evidence of acute bacterial infection (Macfarlane et al., 2001). Thus, Bordetella 
pertussis, Mycoplasma pneumoniae and Chlamydia pneumoniae have been clearly established as 
causes of acute bronchitis. But there is no clear evidence that Streptococcus pneumoniae, 
Haemophilus influenzae or Moraxella catarrhalis cause acute bronchitis in adults without 
underlying lung disease; studies have failed to distinguish between colonization and acute 
infection (Ramirez-Ronda et al., 1981; Treanor & Hayden, 2000). However, these bacteria are 
important causes of superinfections after acute viral respiratory illnesses (Hament et al., 
1999; Peltola & McCullers, 2004). 
The devastating health impact of cigarette smoking is well known (Kuper et al., 2002; 
Stewart et al., 2008). Despite ongoing efforts to reduce smoking prevalence, over 1.1 billion 
people continue to smoke, representing one-sixth of the world’s population (Jha et al., 2002). 
Cigarette smoking is a major risk factor for premature mortality due to cancer, 
cardiovascular and cerebrovascular disease, and chronic obstructive pulmonary disease 
(Dye & Adler, 1994). About half of all smokers will develop a serious smoking-related 
illness, such as chronic obstructive pulmonary disease (COPD), which is characterized by 
irreversible airway obstruction, or cardiovascular disease. Furthermore, about 1–5% of 
smokers will develop a smoking-related malignancy, mostly lung adenocarcinoma or other 
epithelial cell tumours. But cigarette smoking also appears to be a major risk factor for 
respiratory tract infections (Marcy & Merrill, 1987). Both active and passive cigarette smoke 
exposure increase the risk of infections. Passive exposure to tobacco smoke in children 
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contributes significantly to morbidity and mortality (Cheraghi & Salvi, 2009). Children in 
particular, seem to be the most susceptible population for the harmful effects of 
environmental tobacco smoke (ETS). Exposure to ETS amongst children at homes have been 
reported to vary from 27.6% in Africa, 34.3% in South East Asia, 50.6% in Western Pacific, 
and up to 77.8% in Europe (Warren et al., 2008). The morbidity and mortality of infectious 
diseases associated to smoking are not widely appreciated by physicians. The mechanism of 
increased susceptibility to infections in smokers is multifactorial and includes alteration of 
the structural (Dye & Adler, 1994; Marcy & Merrill, 1987) and immunologic host defenses 
(Sopori et al., 1994; Sopori et al., 1998). We reviewed the epidemiology of smoking-related 
lung infections and the mechanisms by which smoking increases the risk of infection. 
2. Mechanisms by which cigarette smoking may predispose to respiratory 
infections 
The specific mechanisms by which cigarette smoking increases the risk of respiratory 
infections are incompletely understood (Saldías et al., 2007; Domagala-Kulawik, 2008). They 
are multifactorial and probably interactive in their effects. Mechanisms by which smoking 
increases the risk of infections include structural changes in the respiratory tract (Dye & 
Adler, 1994) and a decrease in immune response (Sopori et al., 1998). 
2.1 Structural changes caused by smoking 
The ciliated respiratory epithelium, the main target of most respiratory viruses, is the first 
line of defense against harmful environmental agents and protects by sweeping particles 
away in the overlying mucus gel layer, phagocytosing and killing some pathogens, 
maintaining a barrier through tight junctions and priming, activating and recruiting other 
immune cells. Cigarette smoke and many of its components produce structural changes in 
the respiratory tract. These changes include peribronchiolar inflammation and fibrosis, 
increased mucosal permeability, impairment of the mucociliary clearance, changes in 
pathogen adherence, and disruption of the respiratory epithelium (Dye & Adler, 1994). 
These changes are thought to predispose to the development of upper and lower respiratory 
tract infections, which may amplify the cigarette smoke–induced lung inflammation. A 
number of components of cigarette smoke, including acrolein, acetaldehyde, formaldehyde, 
free radicals produced from chemical reactions within the cigarette smoke, and nitric oxide, 
may contribute to the observed structural alterations in the airway epithelial cells (Marcy & 
Merrill, 1987). 
Smoke directly compromises the integrity of this physical barrier, increases the permeability 
of the respiratory epithelium and impairs mucociliary clearance (Dye & Adler, 1994; Jones et 
al., 1980; Burns et al., 1989). Although cigarette smoke has been shown to activate epithelial 
cells to produce pro-inflammatory mediators (Mio et al., 1997), it attenuates the in vitro 
production of pro-inflammatory mediators by epithelial cells following stimulation with 
pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide or double-
stranded RNA (Laan et al., 2004; Bauer et al., 2008). Smoke also induces direct oxidative 
damage to membrane lipids and causes extensive single-strand DNA breaks, triggering 
repair and apoptotic cascades (Kim et al., 2004). Thus, cigarette smoke acutely suppresses 
the respiratory epithelium and chronically can cause damage, inflammation and may 
ultimately transform it. 
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2.2 Effect of cigarette smoke on the lung and systemic immunity 
Cigarette smoke has been shown to affect a wide range of host defense mechanisms (Sopori 
et al., 1994). However, findings between studies can be controversial and sometimes 
contradictory, probably because of differences in smoking history, genetic susceptibility and 
socioeconomic status (such as exercise, nutrition, occupation and ambient air quality, which 
can modify disease). Similar issues apply to animal models and in vitro systems, in which 
parameters of smoke exposure, such as duration, frequency and mode vary markedly 
between studies (Domagala-Kulawik, 2008; Stämpfli & Anderson, 2009). Accordingly, as the 
patterns of smoke exposure are so varied individually and geographically, no single 
experimental smoke exposure system can replicate the diversity of human smoking 
patterns, and each experimental system probably reflects only facets of the overall picture. 
2.2.1 Cell-mediated immune responses 
White blood cell count and distribution in peripheral blood. Smokers usually exhibit an elevated 
peripheral white blood cell count, around 30% higher than that of nonsmokers (Friedman et 
al., 1973; Yeung & Buncio, 1984; Tollerud et al., 1989; Mili et al., 1991). It has been shown a 
significant relationship between the white blood cell count in smokers and the plasma 
concentration of nicotine (Taylor et al., 1986). It has been suggested that nicotine induced 
catecholamine release might be the mechanism for this effect (Friedman et al., 1973). Other 
studies support the hypothesis that cigarette smoking causes bone marrow stimulation (Van 
Eeden & Hogg, 2000). It has been suggested that proinflammatory factors released from 
alveolar macrophages, such as tumor necrosis factor , interleukin (IL) 1, IL-8, and 
granulocyte-macrophage colony-stimulating factor, are probably responsible for the 
stimulation of bone marrow by cigarette smoking. It has been reported the same 
relationship between cigarette smoking and increased leukocyte count in adolescents, 
indicating that there appears to be a rapid effect of cigarette smoking on white blood cell 
count that is unlikely to be due to smoking induced chronic disease conditions as seen in 
adult smokers (Tell et al., 1985). 
Reports of the effects of smoking on the different subsets of lymphocyte T cells are 
conflicting. Light to moderate smokers were reported to have a significant increase in CD3+ 
and CD4+ counts and a trend toward increased CD8+ lymphocyte count (Miller et al., 1982; 
Hughes et al., 1985; Tollerud et al., 1989; Mili et al., 1991). By contrast, studies of heavy 
smokers (over 50 pack-years) reported a decrease in CD4+ and a significant increase in 
CD8+ cell counts. Thus, the decrease observed in the ratio of CD4+ to CD8+ lymphocytes in 
heavy smokers was due predominantly to an increase of CD8+ cells (Ginns et al., 1982). 
These effects appeared to be reversible as soon as 6 weeks after smoking cessation (Miller et 
al., 1982). Other studies have reported no difference in the CD4+ and CD8+ lymphocyte 
counts among moderate smokers (Costabel et al., 1986). Since CD4+ cells facilitate B-cell 
proliferation and differentiation and immunoglobulin synthesis, the decrease in this subset 
observed in heavy smokers might contribute to the increased susceptibility to infections in 
this population. 
Airways and lung parenchyma. Bronchoalveolar lavage studies have demonstrated a marked 
decrease in the absolute number of CD4+ cells, and an increase in CD8+ cells with a lower 
CD4+/CD8+ cell ratio in moderate smokers vs nonsmokers (Leatherman et al., 1984; 
Costabel et al., 1986; Wewers et al., 1998). No significant changes in these variables in the 
peripheral blood were found in this population of moderate smokers, in contrast with the 
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findings in heavy smokers discussed previously. Thus, changes in lymphocyte population in 
the bronchoalveolar lavage in smokers may disclose pathologic changes earlier than in 
blood. Moreover, these findings suggest that smokers have a deficit in cell-mediated 
immunity in the lung alveolus, a site critical in the first-line defense against infection. 
The retention of CD8+ T cells in the lungs of chronic smokers warrants particular attention 
as it is a hallmark of COPD and it is known that these cells can activate alveolar 
macrophages to produce matrix metalloproteinase 12, a potent elastin-degrading enzyme 
that has been linked to emphysema (Hautamaki et al., 1997; Grumelli et al., 2004). 
Furthermore, CD8+ T cells are required for inflammation and tissue destruction in smoke-
induced emphysema in mice (Maeno et al., 2007). Cigarette smoke has also been found to 
promote the retention of virus-specific CD8+ memory effector T cells, but to weaken their 
defensive ability (Gualano et al., 2008). 
Smoking is also associated with significant increases in the percentage of macrophages in 
bronchoalveolar lavage fluid (Wewers et al., 1998). Owing to their strategic positioning 
within the alveolar space, alveolar macrophages have a key role in sensing and eliminating 
microbial agents early in the course of an infection. Cigarette smoking increases the number 
of alveolar macrophages (Sopori et al., 1998) and activates them to produce pro-
inflammatory mediators, reactive oxygen species and proteolytic enzymes (de Boer et al., 
2000; Russell et al., 2002), thereby providing a cellular mechanism that links smoking with 
inflammation and tissue damage. Similar to its effects on the respiratory epithelium, 
cigarette smoke compromises the ability of alveolar macrophages to phagocytose bacteria 
(King et al., 1988; Berenson et al., 2006) and apoptotic cells (Hodge et al., 2007) and to sense 
PAMPs (Drannik et al., 2004; Chen et al., 2007; Gaschler et al., 2008). Importantly, cigarette 
smoke may not simply suppress the function of alveolar macrophages as previously 
suggested, but instead might skew their inflammatory mediator profile. The nature of the 
skewing may be a determinant of disease susceptibility. Accordingly, one study reported a 
distinctive state of activation of alveolar macrophages in smokers that distinguished them 
from those in non-smokers (Woodruff et al., 2005). This highlights a key emerging concept 
— smoke may induce partial M1 deactivation or partial M2 activation of macrophages. The 
balance and intensity of this skewing has direct implications for the immune system and its 
response to disease because effective host defense requires a macrophage activation 
programme that is appropriate for the particular type of pathogen and because M1-type 
macrophages can cause marked lung damage (emphysema), whereas M2-type macrophages 
are linked to tumour progression. The molecular mechanisms of altered alveolar 
macrophage responsiveness and skewing are not presently understood but they are at least 
partially reversible by exposure to the reduced form of glutathione, which implicates 
oxidative damage of effector pathways. The infection risk is compounded by host 
deficiencies or polymorphisms in innate and adaptive immune response genes, in particular 
those encoding pattern recognition receptors, such as mannose-binding lectin, and their 
signal transduction intermediates (Becker & O’Neill, 2007). 
In the lungs, dendritic cells (DCs), which are the most potent antigen-presenting cells and 
are indispensable for the initiation of T cell-mediated immune responses (Mellman & 
Steinman, 2001), are probably highly susceptible to smoke-induced effects because of their 
anatomical position (in the lumen and directly beneath the epithelium of the lung) 
(McComb et al., 2008). Although it is known that the DC-directed chemokine CX3CL1 is 
upregulated in emphysema (McComb et al., 2008), there are only a few studies assessing the 
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effects of smoking on lung DCs in humans and animal models (Tsoumakidou et al., 2008). 
Clinical studies suggest that the number of mature DCs is reduced in the large airways of 
patients with COPD who smoke (Jahnsen et al., 2006). Following smoking cessation, the 
numbers of mature DCs increase and are similar to non-smoking healthy controls. By 
contrast, the number of immature DCs is increased in the small airways of patients with 
COPD compared with individuals who have never smoked and individuals who smoke but 
do not have COPD (McComb et al., 2008). These data indicate that smoking behavior may 
affect DC numbers and maturity state. 
Leukocytes function. Polymorphonuclear leukocytes from the peripheral blood of smokers 
exhibit depressed migration and chemotaxis compared with PMNs from nonsmokers 
(Noble & Penny, 1975; Corberand et al., 1979). The motility and chemotaxis of PMNs are 
depressed in the oral cavity of smokers compared with nonsmokers (Eichel & Shahrik, 1969; 
Noble & Penny, 1975). The whole cigarette smoke, its gas phase and the water-soluble 
fraction are potent inhibitors of PMN chemotaxis (Bridges et al., 1977). Of the water-soluble 
fraction of cigarette smoking, the unsaturated aldehydes (acrolein and crotonaldehyde) 
were the major contributors to the inhibitor properties. The non-volatile components of 
cigarette smoking also inhibit chemotaxis by a mechanism that differs from that of the 
unsaturated aldehydes present in the vapour phase of smoke (Bridges et al., 1977; Bridges & 
Hsieh, 1986). The non-volatile component did not inhibit migration. Nicotine had no effect 
on PMN migration and chemotaxis (Sasagawa et al., 1985). Macrophages from the lungs of 
smokers have a greater inhibitory effect on lymphocyte proliferation than macrophages 
from the lungs of nonsmokers. Thus, the immunosuppressive effects of the macrophages on 
cell-mediated immune response are increased in smokers (Holt, 1987). The release of 
cytokines (TNF, IL-1, IL-2 and IL-6) from macrophages may also be altered in smokers 
(McCrea et al., 1994; Twigg et al., 1994; Ouyang et al., 2000; Hagiwara et al., 2001). 
Hydroquinone, the phenolic compound in cigarette tar, had the most potent inhibitory effect 
of these cytokines, whereas nicotine had little effect. The cytokines IL-1 and IL-6 are 
important in the host defense against infection (Smith, 1988; Luster et al., 1999). Animal 
studies have shown that depletion of these cytokines increases susceptibility to bacterial 
pneumonia. Since PMNs play a significant role in host defense against acute bacterial 
infections, an impairment of PMN functions by smoke may contribute to the increased 
susceptibility of smokers to systemic infections, including bacterial pneumonia. 
Lymphocyte functions. Natural killer (NK) cell activity in peripheral blood has been reported 
to be reduced in smokers compared with nonsmokers (Ferson et al., 1979; Hughes et al., 
1985; Tollerud et al., 1989; Nair et al., 1990). These alterations appear to be reversible, since 
NK activity in ex-smokers was similar to that of a never-smoking group compared with 
smokers (Silverman et al., 1975; Hersey et al., 1983). The recovery period was relatively 
short, as little as 6 weeks (Miller et al., 1982; Hughes et al., 1985). Since NK cells are 
important in the early surveillance response against viral infections and resistance against 
microbial infections (Herberman & Holden, 1978; Herberman, 1980), impairment of NK cell 
activity by cigarette smoking is a potential mechanism for the increased incidence of 
infections among smokers. 
Mounting evidence suggests that natural killer cells have an important role in innate host 
defense against microbial agents and in protective antitumour immune surveillance. This is 
achieved by direct cytotoxicity through perforin and granzymes, CD95 ligand-induced 
apoptosis and pro-inflammatory cytokine and chemokine release (Tollerud et al., 1989; 
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Hamerman et al, 2005). Several studies have shown that NK cell numbers and activity are 
decreased in smokers compared with non-smokers (Swann et al., 2007). Exposure to 
cigarette smoke attenuates the cytotoxic activity and cytokine production of NK cells in 
humans and mice (Lu et al., 2006; Mian et al., 2008), thereby linking NK cell defects to 
increased infection risk and cancer. 
Animal studies have shown that nicotine inhibits the antibody-forming cell response 
through impairment of antigen-mediated signalling in T cells and suppression of 
intracellular calcium response (Geng et al., 1995; Geng et al., 1996; Sopori et al., 1998). It has 
been suggested that nicotine through activation of protein tyrosine kinases and depletion of 
inositol-1,4,5-trisphosphate-sensitive calcium stores in T cells could be a major 
immunosuppressive component in cigarette smoking (Kalra et al., 2000). 
2.2.2 Humoral immune system 
Peripheral blood. The effects of cigarette smoking on humoral immunity have been studied 
extensively (Sopori et al., 1994; Sopori et al., 1998). Several studies have found that smokers 
had serum immunoglobulin levels (IgA, IgG, and IgM) 10% to 20% lower than those of 
nonsmokers (Dales et al., 1974; Ferson et al., 1979; Gerrard et al., 1980; Andersen et al., 1982). 
It has been shown that IgA, IgG, and IgM levels are higher among former smokers than 
current smokers and increased with duration of smoking cessation (Mili et al., 1991). This 
suggests that the effect is reversible, with a return toward the immunoglobulin levels of 
nonsmokers. It has been reported that three months after subjects stopped smoking, IgG and 
IgM but not IgA levels have increased compared with levels during smoking (Hersey et al., 
1983). 
Lung parenchyma. The IgG content of bronchial fluids was found to be twice higher in 
smokers than nonsmokers (Onari et al., 1978; Hersey et al., 1983). A selective increase in 
immunoglobulin levels could be explained either by stimulation of local immunoglobulin 
production or by exudation of plasma immunoglobulin into alveolar spaces in response to 
inhaled cigarette smoke (Warr et al., 1977). The availability of opsonic antimicrobial 
antibodies is essential for optimal function of phagocytes to take up and contain bacteria 
(Reynolds, 1988). The antibody response to a variety of antigens, such as influenza virus 
infection and vaccination is depressed in cigarette smokers (Finklea et al., 1971). 
Autoimmunity has been proposed as a cause of smoke-induced lung disease. B cells are 
abundant in smoke-induced lung disease, and their roles, although obscure, are probably 
greatly underestimated. Cigarette smoke serves as an adjuvant, possibly because it is a 
potent inducer of granulocyte/macrophage colony-stimulating factor production in the 
lungs, which enhances the ability of DCs to present antigen and probably to induce TH2 
type-biased immune responses (Trimble et al, 2009). 
3. Smoking and respiratory infections 
Given the complex nature of the immune system, in which unaffected defense mechanisms 
may compensate for local deficiencies, it is difficult to predict how the impact of cigarette 
smoke on specific host defense pathways affects the overall responses to microbial agents 
(Domagala-Kulawik, 2008). Specifically, it is unclear whether the increased risk of infection 
observed in smokers is due to increased susceptibility to microbial agents, an inability to 
effectively clear infectious agents or exaggerated pro-inflammatory responses to microbial 
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agents (owing to changes in immune homeostasis), thereby evoking symptoms of infection. 
Similar considerations apply to acute exacerbations of COPD that are due to bacterial and 
viral infections (Sethi & Murphy, 2001; Wedzicha, 2004; Papi et al., 2006) and to microbial 
colonization of the airways, which occurs in approximately one third of patients with COPD 
(Patel et al., 2002). 
3.1 Viral infections 
Environmental tobacco smoke exposure increases significantly the risk of lower respiratory 
tract infections in children, especially maternal smoking (Table 1). Using mouse models, it 
has been investigated the effects of cigarette smoke on inflammatory processes, viral 
clearance and secondary immune protection following influenza virus infection (Robbins et 
al., 2006; Gualano et al., 2008; Kang et al., 2008). Cigarette smoke exposure was found to be 
associated with exacerbated pro-inflammatory responses to influenza virus, although 
neither the rate of viral clearance nor the development of influenza virus-specific memory 
responses were compromised. Hence, cigarette smoke mainly affects primary antiviral 
inflammatory processes, whereas secondary immune protection remains intact (Robbins et 
al., 2006). The heightened inflammatory response was associated with increased production 
of pro-inflammatory mediators and mortality. Furthermore, one study (Kang et al., 2008) 
showed that increased inflammation led to accelerated emphysema formation and airway 
fibrosis, providing evidence that altered responsiveness to viral agents may contribute to the 
pathogenesis of emphysema. 
Common cold. Several epidemiological studies support the association between smoking and 
the prevalence of colds and lower respiratory tract symptoms. In a prospective cohort study 
that examined a large group of US Army recruits found an increased risk of upper 
respiratory tract infection in smokers (relative risk: 1.5; 95% confidence interval CI, 1.1-1.8) 
(Blake et al., 1988). It has been reported that smoking status is predictive of the development 
of clinical colds when healthy volunteers are exposed intranasally to a low dose of 
respiratory viruses (Cohen et al., 1993). Viral suspensions were installed into the nares and 
infections were diagnosed on the basis of viral isolation, virus-specific antibody, and clinical 
findings. Smokers had a significantly higher incidence of acute infection (clinical cold) than 
nonsmokers (OR: 2.23; 95% CI, 1.03-4.82). Among virologically confirmed infected 
individuals, smoking was associated with a higher likelihood of symptoms leading to a 
clinical diagnosis (OR: 1.83; 95% CI, 1.00-3.36). The relationship between smoking and 
increased symptoms from viral respiratory infections could be explained by impairment of 
immune processes that limit viral replication or enhancement of inflammatory processes 
involved in the production of symptoms. 
Influenza. Several studies have confirmed the relationship between cigarette smoking and 
the risk of influenza infections (Finklea et al., 1969). Influenza infections are more severe, 
with more cough, acute and chronic phlegm production, breathlessness, and wheezing in 
smokers. Female smokers in the Israeli Army had increased risk of influenza (OR: 1.44; 95% 
CI, 1.03-2.01) and complications associated to influenza infection compared with 
nonsmokers (Kark & Lebiush, 1981). In another study, the incidence of influenza in healthy 
young male recruits was higher among smokers (OR: 2.42; 95% CI, 1.53-3.83) (Kark et al., 
1982). Influenza was more severe among smokers, with a dose-related increase in rate: 30% 
in nonsmokers, 43% in light smokers, and 54% in heavy smokers (p<0.001). Overall, 31.2% 
(95% CI, 16.5-43.1) of influenza cases were attributed to cigarette smoking. 
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Enhanced bacterial adherence has been documented for respiratory cells infected, with 
influenza A virus being responsible for viral-bacterial combination pneumonia (Hament et 
al., 1999). Studies have suggested that inflammatory activation of platelet-activating factor is 
an important factor in the attachment and invasion of cells by pneumococcal strains. 
Cigarette smoking alters platelet-activating factor metabolism and may contribute to the 
increased incidence of bacterial superinfection in people who develop influenza (Miyaura et 
al., 1992; Ichimaru & Tai, 1992). 
 
 
References: 1) Environ Health Prospect 1997;105:302-6; 2) Pediatr Pulmonol 1999;27:5-13.; 3) Eur J Epidemiol 
2000;16:465-8; 4) J Pediatr 2000;137:865-70; 5) An Esp Pediatr 2000;53:339-45; 6) Rev Saude Publica 
2003;37:485-93; 7) Acta Paediatr 2003;92:1314-21; 8) Eur J Epidemiol 2005;20:719-27; 9) Tob Control  
2006;15:294-301; 10) Environ Health Perspect 2006;114:1126-32; 11) Eur J Pediatr 2007;166:455-9; 12) Indian J 
Pediatr 2008;75:335-40; 13) Arch Bronconeumol 2009;45:585-90. 
Table 1. The environmental tobacco smoke (ETS) exposure increases the risk of lower 
respiratory tract infections (LRTI) in children. 
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Although influenza was more severe in smokers, antibody levels to A(H1N1) antigen were 
not significantly higher than those of nonsmokers. Moreover, influenza antibodies wane 
more rapidly in smokers than in nonsmokers (Finklea et al., 1971). This finding suggests that 
smokers are not only at a high risk of influenza, but have an increased susceptibility to new 
attacks afterward (Kark et al., 1982). Influenza rates are similar in vaccinated smokers and 
nonsmokers. However, influenza vaccination can be considered to be more efficacious in 
smokers than nonsmokers because the infection rates are higher in unvaccinated smokers 
(Cruijff et al., 1999). 
Respiratory syncytial virus bronchiolitis. Respiratory syncytial virus (RSV) infection is very 
common in early life; over 95% of children have been infected by two years of age. RSV 
infections are responsible for over 100,000 hospital admissions in the United States 
annually, mostly affecting infants (Moler & Ohmit, 1999). Of RSV-related admissions, 7% 
to 21% will require ventilatory support because of respiratory insufficiency (Everard & 
Milner, 1992). Therefore, RSV infection imposes a significant burden on children early in 
life. Maternal smoking exposure has been shown to reduce lung function in children, and 
several studies suggest that this effect on lung function is attributable primarily to 
exposure during pregnancy (intrauterine cigarette smoke exposure) (Hofhuis et al., 2003). 
Maternal smoking during pregnancy may impair in utero airway development or alter 
lung elastic properties. It has been shown that maternal cigarette smoking, especially 
postnatal, increase the severity of RSV bronchiolitis infection in infants (Gürkan et al., 
2000; Lanari et al., 2002; Bradley et al., 2005). As a preventive measure, it has been 
reported a protective effect of long-term breastfeeding on the risk of lower respiratory 
tract infection during the first year of life, especially in children exposed to environmental 
tobacco smoke (Nafstad et al., 1996). 
Passive smoking and respiratory tract infections in childhood. A study in 1974 reported that 
infants of mothers who smoked had significantly more admissions for bronchitis or 
pneumonia than infants of non-smoking mothers (Harlap & Davies, 1974). The excess 
bronchitis and pneumonia increased with increased number of cigarettes smoked by the 
mother. This excess was mainly seen in infants aged 6 to 9 months. Another study (Colley et 
al., 1974), also found that the incidence of pneumonia and bronchitis in the first year of life 
was associated with parents' smoking habits; the incidence was lowest where both parents 
were non-smokers, highest where both smoked, and lay between these two levels where 
only one parent smoked. During the following three decades, a large number of 
investigations have reported associations between parental smoking and occurrence of 
lower respiratory tract illness in young children (Table 1). A systematic review (Strachan & 
Cook, 1997) of around 50 studies in children up to 3 years, including 38 studies used for 
quantitative analysis, has confirmed these findings. There was consistency in the findings 
between the community and hospital studies. Pooled ratios were found to be 1.57 for 
smoking by either parent and 1.72 for maternal smoking. The reviewers also found that 
there was a significantly increased risk from smoking by other household members in 
families where the mother did not smoke (odds ratio 1.29). In most of the studies also a 
dose-response relationship was evident, and the associations with paternal smoking were 
still present after adjustment for confounding factors. From earlier studies, it appeared that 
the risk was higher during the first 6 months of life, and gradually decreased to slightly 
above normal by age 3 years. However, later studies (Taylor & Wadsworth, 1987) have 
found similar relationships between maternal smoking and lower respiratory illness in 
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children up to 5 years of age. Exposure to passive smoking also seems to increase the risk for 
acute respiratory tract infections in older children (Jedrychowski & Flak, 1997). A dose-
response between the degree of exposure to environmental tobacco smoke and acute 
respiratory infection was found in a cohort of 9-year-old children. Passive smoking 
combined with allergy nearly tripled the risk of acute respiratory tract infections (odds ratio 
3.39). 
3.2 Bacterial infections 
Similarly, cigarette smoke exposure was also found to be associated with increased 
inflammation following challenge with bacterial agents such as Pseudomonas aeruginosa and 
non-typeable H. influenzae (Drannik et al., 2004; Gaschler et al., 2009), two pathogens that are 
associated with COPD exacerbations. Cigarette smoke was associated with increased 
bacterial burden in mice infected with P. aeruginosa, whereas bacterial burden was decreased 
in smoke-exposed animals following infection with non-typeable H. influenzae. Changes in 
the bactericidal activity of alveolar macrophages may contribute to increased bacterial 
burden (Drannik et al., 2004), but it is unclear how infection with non-typeable H. influenzae 
induces decreased bacterial levels; the mechanisms of this are currently being investigated. 
Preliminary data suggest that increased levels of immunoglobulins in the bronchoalveolar 
lavage of smoke-exposed animals might have contributed to this phenomenon. This finding 
provides evidence that compensatory mechanisms may outweigh certain deficiencies and 
help to explain why not all smokers suffer from severe chest infections. As discussed above, 
smoke affects all people who are exposed to it, but the degree and severity is modified by 
many susceptibility determinants. 
Pneumococcal pneumonia. Cigarette smoking is a substantial risk factor for pneumococcal 
pneumonia, especially in patients with chronic obstructive pulmonary disease. However, 
even without chronic obstructive pulmonary disease, smoking is a major risk factor. In a 
population based surveillance study (Pastor et al., 1995), smoking was strongly associated 
with invasive pneumococcal disease in healthy young and middle aged adults, for whom 
pneumococcal vaccination is not currently recommended. Among such individuals with 
invasive pneumococcal disease, 47% were current smokers. The odds ratio (OR) for invasive 
pneumococcal disease was 2.6 (95% CI, 1.9-3.5) for smokers in the 24-to 64-year age group 
and 2.2 (95% CI, 1.4-3.4) for smokers 65 years or older. The attributable risk from smoking 
was 31% and 13% in these 2 groups, respectively. 
A population based case-control study (Nuorti et al., 2000) showed that smoking was the 
strongest independent risk factor for invasive pneumococcal disease among 
immunocompetent adults. The OR was 4.1 (95% CI, 2.4-7.3) for active smoking and 2.5 (95% 
CI, 1.2-5.1) for passive smoke exposure in nonsmokers compared with nonexposed 
nonsmokers. The attributable risk in this population was 51% for cigarette smoking and 17% 
for passive smoking. The risk of pneumococcal disease declined to nonsmoker levels 10 
years after cessation. In another case-control study, current smoking was associated with a 
nearly 2-fold risk of community-acquired pneumonia (OR: 1.88; 95% CI, 1.11-3.19), where 
32% of the risk was attributable to cigarette smoking (Almirall et al, 1999). There was a trend 
toward a dose-response relationship: A 50% reduction in the OR was reported 5 years after 
cessation of smoking. 
In vitro adherence of Streptococcus pneumoniae to buccal epithelial cells has been shown to be 
increased in cigarette smokers (Raman et al., 1983). This increased adherence may persist for 
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up to three years after smoking cessation. Since increased adherence of bacteria to surface cells 
is an established pathogenic step for bacterial colonization and infection in the lung, this may 
contribute to the increased risk of respiratory infection that exists in cigarette smokers. 
Legionnaires disease. Legionnaires disease is a life-threatening lower respiratory tract infection 
responsible for 1% to 3% of community-acquired pneumonia. Diverse environmental factors 
have been identified, and cigarette smoking appears to be an independent risk factor 
(Doebbeling & Wenzel, 1987; Straus et al., 1996). The risk of legionnaires disease was 
significantly increased for smoking (OR: 3.48; 95% CI, 2.09-5.79), specially for persons without 
an underlying disease (OR: 7.49; 95% CI, 3.2-17.1) (Straus et al., 1996). 
Otitis media and exposure to secondhand tobacco smoke. Long term tobacco smoke exposure is a 
risk factor for otitis media and bronchitis in children (Richardson, 1988). In a case-control 
study, children with recurrent otitis media more commonly had exposure to secondhand 
smoke (OR: 1.88; 95% CI, 1.02-3.49; p=0.04). A prospective follow-up of the case group 
showed no significant difference in the clinical course of the children who were exposed to 
secondhand smoke (Kitchens, 1995). In other study, passive smoking was a significant risk 
factor for otitis media with effusion and recurrent otitis media (Ilicali et al, 1999). But only 
maternal smoking was a significant factor (p<0.001). Moreover, in utero exposure to 
cigarette smoke was associated with an increased risk of otitis media. In a study (Stathis et 
al, 1999), acute ear infections were associated with the mother’s consumption of 1 to 9 
cigarettes (OR: 1.6; 95% CI, 1.1-2.5), 10 to 19 cigarettes (OR: 2.6, 95% CI, 1.6-4.2), and 20 or 
more cigarettes (OR: 3.3; 95% CI, 1.9-5.9) per day during pregnancy. For subacute ear 
infections, an association was present with the mother’s consumption of 10 to 19 cigarettes 
(OR: 2.6; 95% CI, 1.4-5.0) and 20 or more cigarettes (OR: 2.8; 95% CI, 1.3-6.0). In utero 
exposure to 20 or more cigarettes per day was also associated with an increased risk of ear 
surgery by 5 years after delivery (OR: 2.9; 95% CI, 1.3-6.6). 
Tuberculosis. Developing tuberculosis disease involves two distinct transitions, with their 
corresponding risk factors: the transition from being exposed to being infected and the 
transition from being infected to developing disease. Several studies have shown that 
smoking is a risk factor for tuberculin skin test reactivity, skin test conversion, and the 
development of active tuberculosis (Table 2). It has been reported an increased relative risk 
of development of tuberculosis for heavy smokers compared with nonsmokers (RR: 2.17; 
95%CI, 1.29-3.63) (Yu et al., 1988). After adjusting for age and heavy drinking, smokers of 20 
years’ or greater duration had 2.6 times (95% CI, 1.1-5.9) the risk of nonsmokers for 
tuberculosis (Buskin et al., 1994). It has been found a strong association between active 
smoking and the risk of pulmonary tuberculosis (Alcaide et al., 1996). Both studies showed a 
dose-response relationship with the number of cigarettes consumed daily. In other study, 
current smokers had a nearly 2-fold increased risk compared with never-smokers (OR: 1.87; 
95% CI, 0.73-4.80) (McCurdy et al., 1997). 
A large case-control study in India examined smoking and tuberculosis in men between 35 
and 69 years of age (Gajalakshmi et al., 2003). The tuberculosis prevalence risk ratio was 2.9 
(95% CI, 2.6-3.3) for ever-smokers compared with never-smokers, and the prevalence was 
higher with a higher level of cigarette consumption. The authors found that the smoking 
attributable fraction of deaths from tuberculosis was 61%, greater than the fraction of 
smoking-attributable deaths from vascular disease or cancer. In a study among children 
living with a patient with active pulmonary tuberculosis, passive smoking confirmed by 
measurement of urinary cotinine levels was a strong risk factor for the development of 
active tuberculosis (OR: 5.39; 95% CI, 2.44-11.91) (Altet et al., 1996). 
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Table 2. Tobacco smoking and active tuberculosis (TB). 
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The biological basis by which tobacco smoking increases tuberculosis risk may be through a 
decrease in immune response, mechanical disruption of cilia function, defects in 
macrophage immune responses, and/or CD4+ lymphopenia, increasing the susceptibility to 
pulmonary tuberculosis (Rich & Ellner, 1994; Onwubalili et al., 1987). 
4. Conclusion 
Smoking appears to be an important risk factor for the acquisition of a lower respiratory 
tract infection (bronchitis, influenza, pneumonia, tuberculosis). This link is likely mediated 
by smoking’s adverse effects on respiratory defenses (structural and immune system 
changes induced by smoking). Considering the high rates of morbidity and mortality from 
pneumonia, tuberculosis and influenza, as well as the economic consequences of work days 
lost from lesser respiratory infections, the merits of smoking cessation are clear. The fact that 
smokers have been shown to be less likely than nonsmokers to undergo vaccination and yet 
are probably at higher risk for influenza and pneumococcal infections highlights the 
importance of targeting this group for vaccination. The available epidemiological evidence, 
from studies worldwide, indicates a dose-response relationship between smoking and 
tuberculosis and that the association is likely to be a causal one. This provides a compelling 
reason for smoking cessation measures to be undertaken to combat the scourge of 
tuberculosis, particularly in developing countries. Physicians should educate their smoking 
patients about their increased risk of respiratory infections, the importance of appropriate 
vaccinations, and the benefits of smoking cessation. 
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